Registration for Oncotype DX Webinar Program

on Thursday, January 14, 2021 at 7:00 PM ET (6:00 PM CT, 5:00 PM MT, 4:00 PM PT).

First Name*

Last Name*

Email Address*

Institution*

City*

State*

* Red indicates a required field

1. Based on the SWOG 8814 and RxPONDER studies, postmenopausal women with ER+, HER2-, N1 breast cancer:

Can all safely be spared chemotherapy
Can safely be spared chemotherapy if their Recurrence Score® result is 0-25 but may benefit from chemotherapy if their Recurrence Score result is over 25
All significantly benefit from the addition of chemotherapy to standard endocrine therapy

2. Based on the ADAPT data presented at SABCS 2020:

ADAPT patients with N0 and N1 breast cancer and Recurrence Score results 0-25 had overall good clinical outcomes without the addition of chemotherapy to standard endocrine therapy
Patients with Recurrence Score results 12-25 and Ki67 ≥10% after pre-operative endocrine treatment experienced an optimal response to neoadjuvant chemotherapy
The Recurrence Score result appears not to be related to chemotherapy response in the neoadjuvant setting

3. The RSClin™ educational tool:

Combines clinical/pathologic information with the Recurrence Score result to refine both prognosis and chemotherapy prediction for individual patients
Is applicable to both node-negative and node-positive breast cancer patients